IP Verse

Immunoglobulin Variable Domains - EP3248986

The patent EP3248986 was granted to Ablynx on Jan 26, 2022. The application was originally filed on May 13, 2015 under application number EP17178990A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3248986

ABLYNX
Application Number
EP17178990A
Filing Date
May 13, 2015
Status
Granted And Under Opposition
Dec 24, 2021
Grant Date
Jan 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PATENT BOUTIQUEOct 25, 2022PATENT BOUTIQUEADMISSIBLE

Patent Citations (62) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS20100301819-
DESCRIPTIONEP2542579
DESCRIPTIONUS2013129727
DESCRIPTIONWO03035694
DESCRIPTIONWO03035695
DESCRIPTIONWO2004003019
DESCRIPTIONWO2004041865
DESCRIPTIONWO2004044204
DESCRIPTIONWO2004062551
DESCRIPTIONWO2005118642
DESCRIPTIONWO2006038027
DESCRIPTIONWO2006040153
DESCRIPTIONWO2006059106
DESCRIPTIONWO2006059108
DESCRIPTIONWO2006122786
DESCRIPTIONWO2006122787
DESCRIPTIONWO2006122825
DESCRIPTIONWO2006129843
DESCRIPTIONWO2007063308
DESCRIPTIONWO2007063311
DESCRIPTIONWO2007066016
DESCRIPTIONWO2007085814
DESCRIPTIONWO2008020079
DESCRIPTIONWO2008068280
DESCRIPTIONWO2008096158
DESCRIPTIONWO2008142164
DESCRIPTIONWO2009058383
DESCRIPTIONWO2009068627
DESCRIPTIONWO2009121804
DESCRIPTIONWO2009127691
DESCRIPTIONWO2009138159
DESCRIPTIONWO2009138519
DESCRIPTIONWO2010042815
DESCRIPTIONWO2010108937
DESCRIPTIONWO2010130832
DESCRIPTIONWO2010142534
DESCRIPTIONWO2011003622
DESCRIPTIONWO2011007586
DESCRIPTIONWO2011042398
DESCRIPTIONWO2011073180
DESCRIPTIONWO2011135026
DESCRIPTIONWO2011144749
DESCRIPTIONWO2011161266
DESCRIPTIONWO2012017574
DESCRIPTIONWO2012130874
DESCRIPTIONWO2012175400
DESCRIPTIONWO2012175740
DESCRIPTIONWO2012175741
DESCRIPTIONWO2013024059
DESCRIPTIONWO2013045707
OPPOSITIONEP3143042
OPPOSITIONUS2011064727
OPPOSITIONWO2006122787
OPPOSITIONWO2009138494
OPPOSITIONWO2011075861
OPPOSITIONWO2012175400
OPPOSITIONWO2012175741
OPPOSITIONWO2013024059
OTHERWO2004041867
SEARCHWO2009138494
SEARCHWO2012175741
SEARCHWO2013024059

Non-Patent Literature (NPL) Citations (32) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BOND et al., J. Mol. Biol., (20030000), vol. 332, pages 643 - 655-
DESCRIPTION- CHEN et al., Methods Mol. Biol., (20090000), vol. 525, page 81-
DESCRIPTION- CHOTHIA et al., Nature, (19890000), vol. 342, pages 877 - 883-
DESCRIPTION- CONRATH et al., JBC 276, (20010000), vol. 10, no. 9, page 7346-
DESCRIPTION- DAVID et al., JBC, (20010000), pages 6370 - 6377-
DESCRIPTION- GOLDMAN et al., Anal. Chem., (20060000), vol. 78, pages 8245 - 8255-
DESCRIPTION- HARMSEN et al., Molecular Immunology, (20000000), pages 579 - 590-
DESCRIPTION- HOLLAND et al., J. Clin. Immunol, (20130000), vol. 33, no. 7, pages 1192 - 203-
DESCRIPTION- HUSSAK et al., Protein Engineering, Design & Selection, (20120000), vol. 25, no. 6, pages 313 - 318-
DESCRIPTION- KABAT et al., Sequence of proteins of immunological interest, N1H Bethesda, MD, Publication No. 91-
DESCRIPTION- KENNETH, A et al., Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, .-
DESCRIPTION- KOLASKAR, FEBS, (19900000), vol. 276, pages 172 - 174-
DESCRIPTION- MANDRUP et al., PLOS One, (20131000), vol. 8, no. 10, page e76834-
DESCRIPTION- MATSUURA et al., International Immunology, (20000000), pages 1183 - 1192-
DESCRIPTION- MUYLDERMANS, Mol. Biotechnol., (20010000), vol. 74, page 27-
DESCRIPTION- NIEBA et al., Protein Engineering, (19970000), vol. 10, pages 435 - 444-
DESCRIPTION- RASHEED et al., Life Sciences, (20000000), vol. 79, pages 2320 - 2328-
DESCRIPTION- RIECHMANN; MUYLDERMANS, J. Immunol. Methods, (20000623), vol. 240, no. 1-2, pages 185 - 195-
DESCRIPTION- SAMBROOK et al., Molecular Cloning: A Laboratory Manual (2nd.Ed.), Cold Spring Harbor Laboratory Press, (19890000), vol. 1-3-
DESCRIPTION- SEONG; MATZINGER, Nature Reviews, (20040000), page 469-
DESCRIPTION- TANHA et al., J. Biol. Chem., (20010000), vol. 276, pages 24774 - 24780-
DESCRIPTION- VU et al., Molecular Immunology, (19970000), pages 1121 - 1131-
DESCRIPTION- XUE, AAPS J., (20130000), vol. 15, no. 3, pages 852 - 5-
OPPOSITION- Anonymous, "Amino Acids Reference Chart", Merck, (20220101), Merck, URL: https://www.sigmaaldrich.com/GB/en/technical-documents/technical-article/protein-biology/protein-structural-analysis/amino-acid-reference-chart#ali, (20221108), XP055979045-
OPPOSITION- Chowell Diego, Sri Krishna, Joseph Blattman, Karen Anderson, "Hydrophobicity is a hallmark of immunogenic MHC class IT cell epitopes (APP2P.111)", J Immunol, (20140501), vol. 192, no. 1 Suppl, page 43.12, XP055979065-
OPPOSITION- Singh B., K C Lee, E Fraga, "Hydrophobic amino acid residues in peptide antigens determine the genetic control of immune responses", Pept Res., (19890101), vol. 2, pages 120 - 127, XP055979057-
OPPOSITION- Kim Dae Young; Hussack Greg; Kandalaft Hiba; Tanha Jamshid, "Mutational approaches to improve the biophysical properties of human single-domain antibodies", Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics, Elsevier, Netherlands, Netherlands , (20140724), vol. 1844, no. 11, doi:10.1016/j.bbapap.2014.07.008, ISSN 1570-9639, pages 1983 - 2001, XP029050318
OPPOSITION- P. A. Barthelemy, H. Raab, B. A. Appleton, C. J. Bond, P. Wu, C. Wiesmann, S. S. Sidhu, "Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, (20080201), vol. 283, no. 6, doi:10.1074/jbc.M708536200, ISSN 00219258, pages 3639 - 3654, XP055040419
OPPOSITION- Vincke Cécile; Loris Remy; Saerens Dirk; Martinez-Rodriguez Sergio; Muyldermans Serge; Conrath Katja, "General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold.", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US , (20090130), vol. 284, no. 5, doi:10.1074/jbc.M806889200, ISSN 0021-9258, pages 3273 - 3284, XP009124408
OPPOSITION- NIEBA L, ET AL, "Disrupting the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterization of an engineered scFv fragment.", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY., GB, GB , (19970101), vol. 10, no. 4, doi:10.1093/protein/10.4.435, ISSN 0269-2139, pages 435 - 444, XP002249462
OPPOSITION- Perchiacca Joseph M; Ladiwala Ali Reza A; Bhattacharya Moumita; Tessier Peter M, "Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.", Reduced elimination of IgG antibodies by engineering the variable region., (20121001), vol. 25, no. 10, doi:10.1093/protein/gzs042, ISSN 1741-0134, pages 591 - 601, XP009173689
OPPOSITION- Kirsty D. Ratanji, Jeremy P. Derrick, Rebecca J. Dearman, Ian Kimber, "Immunogenicity of therapeutic proteins: Influence of aggregation", Journal of Immunotoxicology, Taylor and Francis Group, US, US , (20140401), vol. 11, no. 2, doi:10.3109/1547691X.2013.821564, ISSN 1547-691X, pages 99 - 109, XP055576699

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents